+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Community Acquired Pneumonia (CAP) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Pre Book Price: $ 5216

Original Price: $ 5795

Global Community Acquired Pneumonia (CAP) Market: Overview

Community-acquired pneumonia (CAP) has been a leading cause of mortality among people with infectious diseases and affects people of all age groups. CAP is mainly bacterial in nature and can be caused by a wide range of microorganisms; the most common being streptococcus pneumoniae (pneumococcus). Other pathogens include Haemophilus influenzae, mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella sp.

Increasing prevalence of specific risk factors for CAP in patients has contributed to rising incidence of the infection across various regions. The infection accounts for a significant number of hospital admissions every year. Fuelled by substantial economic and clinical burden of the infection worldwide, a host of treatment modalities to manage CAP has recently emerged. They focus on managing antimicrobial resistance for the most common pathogens, particularly among geriatric population, and evaluating the various vaccination options to prevent these infections. In addition, advancement in diagnostic technologies has increased awareness related to disease incidence, especially in developed nations, thereby fuelling the growth of the market.

The report offers in-depth insight into the key drivers and restraints, current diagnostic trends, emerging treatment modalities, regulatory landscape, market share and size of major segments, and competitive landscape. The strategically motivated insights help various stakeholders gain a better understanding of the market dynamics and identify imminent investment pockets.

Global Community Acquired Pneumonia (CAP) Market: Trends and Opportunities

Rising prevalence of CAP across various regions and the increasing awareness regarding the related diagnostics and therapeutics are the key factors propelling the market. An expanding ageing population, especially in developed countries, is associated with comorbid disease conditions, which has stimulated the demand for advanced CAP treatments. In addition, the concomitant incidence of human immunodeficiency virus (HIV) infection among adult population has increased the morbidity of CAP in some regions, catalyzing the market growth.   

However, the rising case of antibiotic-resistant pathogens has hindered the efficacy of antimicrobial treatments and vaccines. This is likely to impede the growth of the market to an extent. Nevertheless, numerous clinical studies in understanding the etiology of the infection and the launch of new biomarkers that help in better risk stratification of patients affected by CAP are crucial developments creating promising opportunities for market players. In addition, the release of the newer pneumococcal conjugate vaccines is anticipated to expand the treatment modalities of CAP.

Global Community Acquired Pneumonia (CAP) Market: Regional Outlook

Europe and North America are prominent markets for community acquired pneumonia. The growth of the regional markets is expected to be driven by robust healthcare infrastructure and increasing awareness about the availability of advanced biomarkers and diagnostic tests. The advent of new treatment therapies, including vaccines, is anticipated to boost the regional market.

Meanwhile, Asia Pacific is expected to expand at an impressive CAGR over the forecast period. Expanding healthcare infrastructure, driven by booming medical tourism in developed and developing countries, and substantial government funding to augment healthcare facilities are the key factors spurring the demand for CAP treatments in Asia Pacific. Furthermore, increasing discretionary spending on healthcare in various countries is expected to propel the Asia Pacific market in the coming years.

Companies mentioned in the report

Major players operating in the CAP market include KYORIN Pharmaceutical Co. Ltd., AstraZeneca Plc, BioAegis Therapeutics, Inc., Biotest AG, and Pfizer Inc. Key strategies adopted by companies to consolidate their presence across major regions are mergers and acquisitions, partnerships, and collaborations.

Major regions analyzed under this research report are:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.


To receive discount, please click on the button below.

Please click on the button below to customize this report.

 
 
Back To Top